Detalles de la búsqueda
1.
Osimertinib in Patients With Treatment-Naive EGFR-Mutant Non-small Cell Lung Cancer: Overall Survival, Post-progression Management and Budget Impact Analysis in Real-World.
Oncologist
; 2024 Mar 23.
Artículo
en Inglés
| MEDLINE | ID: mdl-38520745
2.
First-Line Osimertinib in Patients with EGFR-Mutant Advanced Non-Small Cell Lung Cancer: Outcome and Safety in the Real World: FLOWER Study.
Oncologist
; 27(2): 87-e115, 2022 03 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-35641222
3.
Real-world data on treatment outcomes in EGFR-mutant non-small-cell lung cancer patients receiving osimertinib in second or further lines.
Future Oncol
; 17(19): 2513-2527, 2021 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-33988036
4.
The emerging role of Schlafen-11 (SLFN11) in predicting response to anticancer treatments: Focus on small cell lung cancer.
Cancer Treat Rev
; 128: 102768, 2024 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-38797062
5.
Small bowel edema and lymphocytic duodenitis as severe reversible gastrointestinal toxicity of selpercatinib in RET fusion-positive non-small cell lung cancer: a case report.
Front Oncol
; 13: 1201599, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-37492479
6.
Secondary prevention and treatment innovation of early stage non-small cell lung cancer: Impact on diagnostic-therapeutic pathway from a multidisciplinary perspective.
Cancer Treat Rev
; 116: 102544, 2023 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-36940657
7.
Clinical Features and Progression Pattern of Acquired T790M-positive Compared With T790M-negative EGFR Mutant Non-small-cell Lung Cancer: Catching Tumor and Clinical Heterogeneity Over Time Through Liquid Biopsy.
Clin Lung Cancer
; 21(1): 1-14.e3, 2020 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-31601525
Resultados
1 -
7
de 7
1
Próxima >
>>